A patient with heart failure has met with his primary care provider and begun treatment with an angiotensin-converting enzyme (ACE) inhibitor. When the patient begins treatment, the nurse should prioritize what assessment?

Choice A reason: Pedal pulses are assessed to determine peripheral perfusion and the presence of peripheral arterial disease. While important in a general cardiovascular assessment for heart failure, they are not directly affected by the initiation of ACE inhibitor therapy in a way that requires "priority" monitoring compared to systemic hemodynamic changes. Choice B reason: Appetite can be affected by various medications or the progression of heart failure (cardiac cachexia). However, nutritional status is a chronic concern rather than an acute safety priority. ACE inhibitors are not typically associated with immediate, life-threatening changes in appetite that would supersede cardiovascular monitoring. Choice C reason: ACE inhibitors prevent the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, and reduce aldosterone secretion. This leads to vasodilation and reduced fluid volume, which can cause significant hypotension, especially "first-dose hypotension." Monitoring blood pressure is critical to ensure the patient does not experience syncope or impaired organ perfusion. Choice D reason: Oxygen saturation is a vital measure of respiratory function and gas exchange, which is often compromised in heart failure. However, the specific pharmacological action of an ACE inhibitor targets the renin-angiotensin-aldosterone system (RAAS) to lower blood pressure and reduce afterload, making hemodynamic monitoring the most direct priority when starting this drug.